Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: A randomized controlled trial

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Allen, Elizabeth N ^a   Little, Francesca ^a   Camba, Tunisio ^b   Cassam, Yasmin ^b   Raman, Jaishree ^c   Boulle, Andrew ^a   Barnes, Karen I ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MINISTRY OF HEALTH   (Mozambique)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; AXILLA TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MOZAMBIQUE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; PARASITOLOGY; PLASMODIUM FALCIPARUM; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALARIA, FALCIPARUM; MALE; MOZAMBIQUE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PYRIMETHAMINE; SULFADOXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67749133714     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-141     Document Type: Article

References (36)

1. World Health Organization, Regional Office for Africa. Country health system fact sheet 2006 Mozambique. http://www.who.int/countries/moz/moz/en/
2. Chloroquine-resistant malaria. TE Wellems CV Plowe, J Infect Dis 2001 184 770 76 10.1086/322858 11517439 (Pubitemid 32826429)
3. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Minireview. NJ White, Antimicrob Agents Chemother 1997 41 1413 22 9210658
4. Effects of artemisinin derivatives on malaria transmissibility. RN Price F Nosten C Luxemburger FO ter Kuile L Paiphun T Chongsuphajaisiddhi NJ White, Lancet 1996 347 1654 8 10.1016/S0140-6736(96)91488-9 8642959 (Pubitemid 26177386)
5. Artemisinin-based combination treatment of falciparum malaria. F Nosten NJ White, Am J Trop Med Hyg 2007 77 Suppl 6 181 92
6. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. L von Seidlein P Milligan M Pinder K Bojang C Anyalebech R Gosling, Lancet 2000 355 352 57 10.1016/S0140-6736(99)10237-X 10665554
7. World Health Organization: Guidelines for the treatment of malaria. http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
8. Artesunate combinations for treatment of malaria: meta-analysis. International Artemisinin Study Group, Lancet 2004 363 9 17 10.1016/S0140- 6736(03)15162-8 14723987 (Pubitemid 38076919)
9. WorldWide Antimalarial Resistance Network (WARN). http://www.wwarn.org/ home/index.php
10. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. J Raman B Sharp I Kleinschmidt C Roper E Streat V Kelly KI Barnes, Am J Trop Med Hyg. 2008 78 2 256 261 18256426
11. Seven years of regional malaria control collaboration-Mozambique, South Africa and Swaziland. BL Sharp I Kleinschmidt E Streat R Maharaj KI Barnes DN Durrheim, Am J Trop Med Hyg. 2007 76 1 42 47 17255227
12. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. JY Carter MP Loolpapit OE Lema JL Tome NJD Nagelkerke WM Watkins, Am J Trop Med Hyg 2005 73 166 70 16014852
13. Severe falciparum malaria. World Health Organization, Trans R Soc Trop Med Hyg 2000 94 Suppl 1 62
14. World Health Organization, Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO/MAU96.1077 1996
15. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. http://www.who.int/malaria/docs/ProtocolWHO.pdf
16. World Health Organization, Basic malaria microscopy Part 1 Learner's Guide Switzerland: Macmillan/Presses Centrales 1991
17. PCR and strain identification in Plasmodium falciparum. J Wooden S Keyes CH Sibley, Parasitol Today 1993 303 5 10.1016/0169-4758(93)90131-X 15463789 (Pubitemid 23217730)
18. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. LC Ranford-Cartwright J Taylor T Umasunthar LH Taylor HA Babiker B Lell JR Schmidt-Ott LG Lehman D Walliker PG Kremsner, Trans R Soc Trop Med Hyg. 1997 91 6 719 724 10.1016/S0035-9203(97)90539-3 9509189 (Pubitemid 28019926)
19. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. CV Plowe JF Cortese A Djimde OC Nwanyanwu WM Watkins PA Winstanley JG Estrada-Franco RE Mollinedo JC Avila JL Cespedes D Carter OK Doumbo, J Infect Dis 1997 176 1590 6 10.1086/514159 9395372
20. D Collett, Modelling survival data in medical research Chapman and Hall/CRC. Press LLC 2 2003
21. Department of Health, Guidelines for good practice in the conduct of clinical trails in South Africa Department of Health, Pretoria, South Africa 2000
22. Naturally acquired immunity to Plasmodium falciparum malaria in Africa. L Haviid, Acta Trop Acta Trop. 2005 95 3 270 275 10.1016/j.actatropica.2005.06. 012 (Pubitemid 41207292)
23. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. JJ Aponte C Menendez D Schellenberg E Kahigwa H Mshinda P Vountasou M Tanner PL Alonso, PLoS Med. 2007 4 7 e242 10.1371/journal.pmed.0040242 17676985 (Pubitemid 47196228)
24. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. G Dorsey MR Kamya G Ndeezi JN Babirye CR Phares JE Olson ET Katabira PJ Rosenthal, Am J Trop Med Hyg. 2000 62 6 686 692 11304055
25. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. KI Barnes F Little PJ Smith A Evans WM Watkins NJ White, Clin Pharmacol Ther. 2006 80 6 582 596 10.1016/j.clpt.2006.08.016 17178260 (Pubitemid 44920218)
26. Antimalarial dosing regimens and drug resistance. KI Barnes WM Watkins NJ White, Trends Parasitol. 2008 24 3 127 134 18262470
27. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. DJ Terlouw JM Courval MS Kolczak OS Rosenberg AJ Oloo PA Kager AA Lal BL Nahlen FO ter Kuile, J Infect Dis 2003 187 467 76 10.1086/367705 12552431 (Pubitemid 36184588)
28. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. JM Govere JJ la Grange DN Durrheim JA Freese BL Sharp A Mabuza N Mngomezulu BL Bredenkamp, Trans R Soc Trop Med Hyg 1999 93 644 10.1016/S0035-9203(99)90082-2 10717756
29. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. CV Plowe JF Cortese A Djimde OC Nwanyanwu WM Watkins PA Winstanley JG Estrada-Franco RE Mollinedo JC Avila JL Cespedes D Carter OK Doumbo, J Infect Dis 1997 176 Suppl 6 1590 6 10.1086/514159
30. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RA Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 Suppl 3 380 8 10.1086/338566 (Pubitemid 34107252)
31. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. CV Plowe C Roper JW Barnwell CT Happi HH Joshi W Mbacham SR Meshnick K Mugittu I Naidoo RN Price RW Shafer CH Sibley CJ Sutherland PA Zimmerman PJ Rosenthal, Malar J 2007 6 121 17822535 10.1186/1475-2875-6-121 (Pubitemid 47566322)
32. Age, temperature, and parasitaemia predict chloroquine treatment failure and anaemia in children with uncomplicated Plasmodium falciparum malaria. DH Hamer WB MacLeod E Addo-Yobo CP Duggan B Estrella WW Fawzi JK Konde-Lule V Mwanakasale ZG Premji F Sempértegui FP Ssengooba K Yeboah-Antwi JL Simon, Trans R Soc Trop Med Hyg 2003 97 Suppl 4 422 8 10.1016/S0035-9203(03)90076-9 (Pubitemid 39186024)
33. Predictors of treatment failure in multiple drug resistant falciparum malaria: results from a 42-day follow-up of 224 patients in Eastern Thailand. AL Fontanet AM Walker, Am J Trop Med Hyg 1993 49 4 465 72 8214276
34. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. C Luxemburger F Nosten SD Raimond T Chongsuphajaisiddhi NJ White, Am J Trop Med Hyg. 1995 53 5 522 525 7485711
35. In vivo assessment of drug efficacy against plasmodium falciparum malaria: duration of follow-up. K Stepniewska WR Taylor M Mayxay R Price F Smithuis JP Guthmann K Barnes HY Myint M Adjuik P Olliaro S Pukrittayakamee S Looareesuwan TT Hien J Farrar F Nosten NP Day NJ White, Agents Chemother. 2004 48 11 4271 4280 10.1128/AAC.48.11.4271-4280.2004 (Pubitemid 39434886)
36. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. AP Alker V Mwapasa A Purfield SJ Rogerson ME Molyneux DD Kamwendo E Tadesse E Chaluluka SR Meshnick, Antimicrob Agents Chemother. 2005 49 9 3919 3921 10.1128/AAC.49.9. 3919-3921.2005 16127071 (Pubitemid 41233050)